2048 Ventures’ Post

Cynata Therapeutics (ASX:CYP) - JMM partnered with éthica capital to host an exclusive event in Sydney on 2nd May, 2024, showcasing some of ASX's most promising Small Caps. CYP is pioneering the development of Cymerus™️, an exclusive stem cell platform designed for the efficient production of high-quality mesenchymal stem cell (MSC)-based therapies.   Their primary candidate, CYP-001, displays promising results in addressing steroid-resistant acute graft-versus-host disease (GvHD), with ongoing clinical trials targeting GvHD, osteoarthritis, and diabetic foot ulcers (DFU).   The Cymerus technology stands out due to its ability to generate consistent MSCs from a single cell bank, offering significant advantages over traditional methods. These advancements hold potential for addressing various diseases, as evidenced by preclinical models. Hear more from CEO and Managing Director, Dr Kilian Kelly. #asx #asxnews #investors

In business news,  āshibio, a privately held biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, exited stealth mode with $40 million in seed and Series A financing. MPM BioImpact led the Series A round, with contributing funds from Agent Capital, YK Bioventures, and Mirae Asset Venture Investment. āshibio licensed andecaliximab, a humanized antibody that specifically inhibits MMP-9, from Gilead Sciences, Inc. Andecaliximab has been administered to approximately 1,000 patients in previous clinical trials. āshibio plans to initiate a Phase 2/3 trial of andecaliximab in the second half of 2024 in patients with FOP. #mabs https://lnkd.in/e7Be3ADN

Developing drugs and therapies to provide the best possible outcomes for patients takes precision and expertise. 💊 Translational modelling is essential in drug development in order to improve the efficiency and success rate of bringing these solutions to patients. 🔬 With Physiomics plc, you can de-risk this critical step by leveraging our expertise with computational modelling and simulation to make the most informed decisions and optimise outcomes. 💡 Find out more about how our translational modelling solutions can make a difference in drug development: https://bit.ly/3r0iC4E #Cancer #DrugDevelopment #VirtualTumour #TranslationalModelling #CancerDrugs #CancerSimulation #CombinationTherapies #BioTech #Pharma #PYC

Radiopharma landscape 👏 50+ companies, 2 therapies hitting the market and mutiple companies emerging from pre to phase I/II quickly and late stages too. Intruiging to see a very established biotech space gaining investor confidence and acquisitions recently. #biotechnology #oncology #radiopharmaceuticals #biopharma

Exploring Strategic Growth: Cizzle Biotechnology's 2023 Annual Report We are excited to share insights from Cizzle Biotechnology Holdings plc's 2023 Annual Report, which highlights a year of strategic partnerships and advancements in lung cancer detection technologies. Dive into the details of their financial performance, strategic licensing initiatives, and the steps they're taking towards minimizing environmental impact. Discover how these initiatives align with our mission to innovate in healthcare and what lies ahead for Cizzle Biotechnology. 🔗 Read the full summary on our blog: https://buff.ly/4f6vShk #CizzleBiotechnology #AnnualReport #LungCancerAwareness #HealthcareInnovation

Full presentation on how to heal multifactorial diseases with one bacteria:

New opportunities and trends in the Patient Derived Xenograft (PDX) Models Market? Our market research report has identified the fastest-growing segments of the industry, giving you the insights, you need to make strategic business decisions. Whether you're a start-up or an established company, this report is a valuable resource for growth. Key Market Players- Crown Bioscience, The Jackson Laboratory, Champions Oncology, Inc., Charles River Laboratories, WuXi AppTec, Oncodesign Precision Medicine - OPM, Horizon Discovery, Pharmatest Services, Hera BioLabs, EPO Berlin-Buch GmbH, XenTech, UROLEAD. Contact - angela.v@marketinsightsreports.com or sales@marketinsightsreports.com to get free sample of this report. #marketresearch #researchreport #sales #healthcareinnovations

AssayQuant, an innovative life science company, supports the drug discovery process and enables the development of next-generation drugs targeting kinase and phosphatase enzyme activity.   AssayQuant’s mission is to support the development of more effective therapies for cancer, chronic inflammation, neurodegeneration, and other serious conditions.   This is an exciting investment opportunity to join AssayQuant’s convertible note and additional raise of $3 million, that will convert into their Series B raise of $12 million to $15 million total see link https://bit.ly/3OSET2C for additional information Since January of 2023, AssayQuant have raised $4.4 million primarily from existing investors who are thrilled with the stellar execution they have delivered. AssayQuant's proprietary technology is exclusively licensed from MIT and is integrated into a growing menu of catalog products and CRO services that supports the drug discovery process and enables the development of more effective therapies targeting kinase and phosphatase enzyme activity www.assayquant.com. #assayquant #mit #convertiblenote #lifescience #biotech #cancer #neurodegeneration #capitalengine #poweringonlinecapitalmarkets #drugdiscovery Erik Schaefer AssayQuant Technologies Inc.

𝗙𝗿𝗶𝗱𝗮𝘆 𝗤𝘂𝗶𝗰𝗸-𝗙𝗶𝗿𝗲 🔥  𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗙𝘂𝗻𝗱𝗶𝗻𝗴 💊🧬 Summit Therapeutics, Inc. have obtained a $200M investment from institutional investors for their Bispecific antibody, lung cancer. They are focused on the discovery, development, and commercialisation of patient, physician, caregiver and societal-friendly medicinal therapies Envisagenics are a start-up founded by scientists from Cold Spring Harbor Laboratory and have raised $25M in series B funding for their AI-Enabled Novel Therapeutic Pipeline Vilya has been back by NVIDIA and top VC firms. A biotech spinout from Seattle’s Institute for Protein Design. They announced an expanded $71 million Series A investment round for their advanced machine learning and AI techniques to help develop so-called macrocyclic drugs, a promising new type of medicine. #Biotech #Funding #MasonHarding #BiotechSearchPartner